TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03033329
Drug: Single intravenous doses of MRX-4
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous single escalating doses of MRX-4
Study: NCT03033329
Drug: Multiple intravenous doses of MRX-4
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple ascending doses of MRX-4 given intravenously twice daily for 10 days
Study: NCT02093910
Drug: Monosialotetrahexosylganglioside
Normalized name: Monosialotetrahexosylganglioside
DrugBank: Ganglioside GM1 (DB16948)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00139217
Drug: iNO
Normalized name: INO
DrugBank: Inosine (DB04335)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00924703
Drug: rAvPAL-PEG
Normalized name: rAvPAL-PEG
DrugBank: Pegvaliase (DB12839)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The doses are planned to be in the same range as those tested in PAL-002 or PAL-004 and then modified either by increasing or decreasing the dose, adhering to an upper limit up to 5.0 mg/kg per week or 375 mg/week, considering each subject's individual responses related to safety and efficacy.
Study: NCT00628355
Drug: lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Women randomized for this treatment was submitted to 2mL of lidocaine 0,5% without vasoconstrictor, directly and perpendicularly on trigger point. Patients received lidocaine injections once a week for 4 weeks
Study: NCT02855944
Drug: Rucaparib
Normalized name: Rucaparib
DrugBank: Rucaparib (DB12332)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets of rucaparib, at a dose of 600 mg, will be taken orally twice a day
Study: NCT02421601
Drug: Condoliase
Normalized name: CONDOLIASE
DrugBank: Condoliase (DB12793)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 1.25 U, intradiscal injection, one time
Study: NCT00742976
Drug: Insulin Detemir; Insulin Insulatard
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dosage is individual but fixed in study period (if possible). Detemir is given once daily, Insulatard is given twice daily.
Study: NCT00742976
Drug: Insulin Detemir, Insulin Insulatard
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fixed doses in study period (if possible). Insulin Detemir once daily, Insulin Insulatard twice daily.
Study: NCT04408911
Drug: Midazolam vs. Lormetazepam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In this retrospective analysis we compared critically ill ICU patients receiving midazolam to those receiving lormetazepam.
Study: NCT00431249
Drug: Cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00745914
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral Pioglitazone 15mg daily for 12 weeks, then 30mg daily for 36 weeks
Study: NCT01329913
Drug: MK-6325
Normalized name: MK-6325
DrugBank: MK-6325 (DB15249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 100 mg capsules, orally, once per day for 7 days
Study: NCT01329913
Drug: Placebo to MK-6325
Normalized name: MK-6325
DrugBank: MK-6325 (DB15249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 100 mg capsules, orally, once per day for 7 days
Study: NCT01329913
Drug: MK-6325
Normalized name: MK-6325
DrugBank: MK-6325 (DB15249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four 100 mg capsules, orally, once per day for 7 days
Study: NCT01329913
Drug: Placebo to MK-6325
Normalized name: MK-6325
DrugBank: MK-6325 (DB15249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four 100 mg capsules, orally, once per day for 7 days
Study: NCT01329913
Drug: MK-6325
Normalized name: MK-6325
DrugBank: MK-6325 (DB15249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eight 100 mg capsules, orally, once per day for 7 days
Study: NCT01329913
Drug: Placebo to MK-6325
Normalized name: MK-6325
DrugBank: MK-6325 (DB15249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eight 100 mg capsules, orally, once per day for 7 days
Study: NCT03444012
Drug: ticagrelor 90 mg
Normalized name: ticagrelor 90 MG
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: persistence and adherence on ticagrelor in ACS patients
Study: NCT01530243
Drug: Terazosine
Normalized name: Terazosine
DrugBank: Terazosin (DB01162)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mg BID
Study: NCT01530243
Drug: Tolterodine
Normalized name: Tolterodine
DrugBank: Tolterodine (DB01036)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mg daily
Study: NCT01530243
Drug: Tolterodine + Terazosin
DrugBank: Tolterodine (DB01036)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2mg daily and 2mg BID
Study: NCT00684177
Drug: Retapamulin Ointment, 1%
DrugBank: Retapamulin (DB01256)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse taper puncture tip caps.
Study: NCT01446809
Drug: Ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01446809
Drug: Pazopanib Hydrochloride
Normalized name: Pazopanib Hydrochloride
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT03776656
Drug: Allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily oral administration
Study: NCT00445328
Drug: Dalteparin (Fragmin)
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin 5000 IU once daily subcutaneously for 6-14 days.
Study: NCT00445328
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin 5000 IU thrice daily subcutaneously for 6-14 days.
Study: NCT03532217
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: -Nivolumab is a human monoclonal antibody (mAb)
Study: NCT03532217
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: -Ipilimumab is a mAb blocking the inhibitory signal mediated by cytotoxic T Lymphocyte-associated antigen 4 (CTLA-4), a protein receptor that downregulates the immune system.
Study: NCT01852383
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients were evaluated weekly for the first 6 weeks and every two weeks for the next 6 weeks. At 0, 1, 4, 8, and 12 weeks, the study psychiatrist completed the Cornell Dysthymia Rating Scale , Clinical Global Impression (CGI) scale, and side effect ratings using the Treatment Emergent Symptom Scale. The research rater completed a SCID-P at baseline and the 24-item HAM-D at each visit, and the patient completed the Beck Depression Inventory-II at each visit.~Adverse events: All adverse events and serious adverse events were documented.~The maximum duration of delay before active treatment (medication or psychotherapy) was 1 week.~Dropout: Patients who had a CGI score of 6 or 7 for two weeks during the second half of the study were dropped by the investigator from the trial.
Study: NCT02292628
Drug: Infusion of mesenchymal stem cells from adipose tissue
Normalized name: Longeveron mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02099201
Drug: ACT-389949 40 mg
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02248129
Drug: Telmisartan and hydrochlorothiazide
Normalized name: Telmisartan and Hydrochlorothiazide Tablets
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02099201
Drug: ACT-389949 200 mg
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Predicted dose
Study: NCT02099201
Drug: ACT-389949 800 mg
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Predicted dose
Study: NCT02099201
Drug: ACT-389949 (Group C1 dose to be selected)
Normalized name: C1-INH
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02099201
Drug: ACT-389949 (Group C2 dose to be selected)
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02565810
Drug: Adalimumab PFS and Pen
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01356511
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone, po, 1 mg/kg/d, for 4 weeks.
Study: NCT01356511
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone, po, 40 mg/d, for 4 days.
Study: NCT00110266
Drug: Deferasirox
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 20 mg/kg/day over one year in patients with MDS
Study: NCT01934153
Drug: [14C]Umeclidinium 18.5 mg
DrugBank: Clidinium (DB00771)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Umeclidinium will be supplied as clear, colorless solution, free from visible particulates, single dose, topical solution in clear glass jars. Dosage of 18.5 mg of Umeclidinium per gram is equivalent to 22 mg per gram of the bromide salt.
Study: NCT00362804
Drug: Tetrabenazine
Normalized name: Tetrabenazine
DrugBank: Tetrabenazine (DB04844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The initial TBZ dose will be 12.5 mg and the dose will be increased to 25 mg at Week 2. Thereafter, the dose can be decreased to 12.5 mg or increased in 12.5 mg increments at weekly intervals, depending on clinical response and tolerability, to a maximum of 75 mg/day. For 37.5 and 50 mg daily, administration will be BID i.e., 25 mg QAM, 12.5 or 25 mg QHS. For 62.5 or 75 mg daily, a TID dosing will be employed i.e., 25 mg QAM, 12.5 or 25 mg QPM, 25 mg QHS
Study: NCT00975143
Drug: Isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg/kg/day for 4 weeks, and 1 mg/kg/day for 16 weeks, taken orally, twice daily.
Study: NCT00550901
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00550901
Drug: dexrazoxane hydrochloride
Normalized name: Dexrazoxane Hydrochloride
DrugBank: Dexrazoxane (DB00380)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00293384
Drug: Aprepitant
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant 80mg once daily in the morning on days 2 and 3
Study: NCT00293384
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone orally 10 mg 1 hour prior to cyclophosphamide administration.
Study: NCT00293384
Drug: Granisetron hydrochloride
Normalized name: Granisetron Hydrochloride
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Kytril 1 mg orally or I.V., 1 hour prior to cyclophosphamide administration.
Study: NCT00225355
Drug: Rosiglitazone
Normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001720
Drug: Alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01283542
Drug: Pasireotide LAR
Normalized name: pasireotide LAR 20 MG Injection
DrugBank: Pasireotide (DB06663)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 and 40 mg of powder in vials and 2 mL of vehicle in ampoules (for reconstitution) administered as a depot intragluteal IM (intramuscular) injection
Study: NCT02478580
Drug: Nuvigil
Normalized name: Nuvigil
DrugBank: Armodafinil (DB06413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive Nuvigil before the surgery
Study: NCT01348555
Drug: Bronchodilatator
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00112177
Drug: Itopride Hydrochloride
Normalized name: Itopride hydrochloride
DrugBank: Itopride (DB04924)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000479
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive 100 mg of aspirin every other day.
Study: NCT00000479
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive 600 IU of vitamin E every other day.
Study: NCT03463070
Drug: rectal misoprostol 600mg
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 70 women who received 600 mg misoprostol postoperatively at operating theatre
Study: NCT00247455
Drug: Low fibre breakfast cereal (puffed rice/cornflakes)
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00247455
Drug: High fibre cereal (All Bran/Bran Flakes)
Normalized name: bran
DrugBank: Elafibranor (DB05187)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00140075
Drug: Epirubicin with a Taxane
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin = 75 mg/m2 per cycle~Taxane = paclitaxel = 175 mg/m2 or docetaxel = 75 mg/m2
Study: NCT01496157
Drug: 18F-DCFBC
Normalized name: (18F)-Fluoride
DrugBank: DCFBC F-18 (DB14772)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A bolus of 10 mCi (370 MBq) \[9-11 mCi (333-407 MBq)\] of 18F-DCFBC will be injected into the IV line by slow IV push.
Study: NCT01822613
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In the Phase II portion of the study Paclitaxel is one of the 3 physician's choice drug which allows single-agent paclitaxel to be used per manufacturer's label.
Study: NCT01231165
Drug: Nitrates, clopidogrel, aspirin, statins
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Comparative Efficacious Research
Study: NCT03138668
Drug: Ropivacaine Injection
Normalized name: ROPivacaine Injection
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All 20 study participants will receive both treatment Low dose Ropivacaine and High dose Ropivacaine in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment Low dose Ropivacaine and High dose Ropivacaine will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment Low dose Ropivacaine in the right lower extremity, treatment High dose Ropivacaine will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control.
Study: NCT01822613
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the Phase II portion of the study Docetaxel is one of the 3 physician's choice drug which allows single-agent docetaxel to be used per manufacturer's label.
Study: NCT01822613
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In the Phase II portion of the study Irinotecan is one of the 3 physician's choice drug which allows single-agent irinotecan to be used per manufacturer's label
Study: NCT00820924
Drug: LAPATINIB
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: LAPATINIB 1500MG ORAL DOSE DAILY
Study: NCT01588002
Drug: danoprevir
Normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple oral doses
Study: NCT01588002
Drug: efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: multiple oral doses
Study: NCT01588002
Drug: ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: multiple oral doses
Study: NCT01792518
Drug: Linagliptin 5mg
Normalized name: LINAGLIPTIN 5MG TAB
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00481728
Drug: Tolterodine
Normalized name: Tolterodine
DrugBank: Tolterodine (DB01036)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose per patient as determined by protocol.
Study: NCT02162862
Drug: bupropion-SR
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02229877
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg oral capsules administered twice daily for 8.5 days
Study: NCT02229877
Drug: Gefapixant
Normalized name: Gefapixant
DrugBank: Gefapixant (DB15097)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Gefapixant oral tablet (25 mg administered as a divided 50 mg tablet) administered twice daily for 2 days
Study: NCT02229877
Drug: Gefapixant
Normalized name: Gefapixant
DrugBank: Gefapixant (DB15097)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Gefapixant oral tablet (50 mg tablet) administered twice daily for 8 days
Study: NCT02229877
Drug: Gefapixant
Normalized name: Gefapixant
DrugBank: Gefapixant (DB15097)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Gefapixant oral tablet (150 mg administered as three 50 mg tablets) administered twice daily for 8 days
Study: NCT01332734
Drug: Magnesium Sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 gram in 1 hour
Study: NCT00192075
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 900 mg/m2 IV over 90 minutes after Folinic Acid weekly for 6 weeks every 8 weeks until progression.
Study: NCT00192075
Drug: avastin
Normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 milligrams per kilogram (mg/kg)
Study: NCT00192075
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 85 mg/m2 as a 2-hour infusion on Day 1 of a 14 day cycle.
Study: NCT00649116
Drug: Metoprolol Tartrate Tablets 100 mg
Normalized name: Metoprolol Tartrate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg, single dose fed
Study: NCT04173338
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: start at 20mg then increase by 20mg every cycle or until there's a dose-limiting toxicity.
Study: NCT04173338
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Start with 400mg/m2, then increase and maintain 500mg/m2 unless dose-limiting toxicity.
Study: NCT02224872
Drug: Thymoglobulin
Normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg IV on Day -9 2 mg/kg IV on Days -8, -7
Study: NCT02224872
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/M2 IV on days -6 to -2
Study: NCT02224872
Drug: Mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg/kg IV on days 3, 4
Study: NCT02224872
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For patients 18 years or older, tacrolimus will be given per institutional standards; may be increased or later changed to a PO BID schedule. Treatment to continue until Day 365 or longer if GVHD present
Study: NCT01485978
Drug: Ramipril
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramipril (Delix) tablets containing 2.5 mg ramipril, oral application with 1 to 6 mg per body surface area ramipril once daily for 3 years.
Study: NCT04608266
Drug: Camostat Mesylate
Normalized name: camostat mesylate
DrugBank: Camostat (DB13729)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camostat mesylate, oral administration 600mg/day (2 x 100mg tablets every 8 hours) for 14 days
Study: NCT03906669
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PO daily for 14 days
Study: NCT03906669
Drug: Letrozole and Prometrium
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PO daily for 14 days
Study: NCT03906669
Drug: Tamoxifen and Prometrium
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PO daily for 14 days
Study: NCT01485978
Drug: placebo to ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral application of placebo to ramipril, once daily with 1 to 6 mg per body surface area for 3 years or until disease progression.
Study: NCT00279708
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo vs. Atorvastatin
Study: NCT02753712
Drug: Fluticasone/Formoterol BAI
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02753712
Drug: Fluticasone/Vilanterol DPI (Relvar Ellipta DPI)
DrugBank: Vilanterol (DB09082)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01485978
Drug: Ramipril
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral treatment with 1 to 6 mg per body surface area ramipril once daily for 3 years as per protocol.
Study: NCT00930202
Drug: Conivaptan (Vaprisol)
Normalized name: conivaptan Injection [Vaprisol]
DrugBank: Conivaptan (DB00872)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conivaptan (Vaprisol) will be administered in a single dose of 20 mg, mixed with 100 mL of 5% dextrose in water, and delivered over 30 minutes.
Study: NCT00003060
Drug: busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003060
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02363829
Drug: Nelfinavir
Normalized name: Nelfinavir
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00722293
Drug: Pazopanib (GW786034)
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Arm A - daily administration of pazopanib on Days 1 through 21 starting at 200mg with a maximum dose of 800mg; Arm B daily administration of pazopanib on Days 1 through 8 of a 3-week cycle starting at 200mg escalating to a maximum dose of 800mg; Arm C daily dose of pazopanib on Days 14 through 21 of a 3-week cycle starting at 200mg escalating to a maximum dose of 800mg; Arm D once daily administration of pazopanib (according to schedule selected from Arm A, B, or C) starting at 400mg escalating to a maximum dose of 800mg